Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$40.61 +3.5%	$37.48	$23.42 ▼ $62.58	$2.19B	0.87	569,585 shs	777,329 shs
ARWR Arrowhead Pharmaceuticals	$27.80 +8.3%	$18.28	$9.57 ▼ $27.86	$3.05B	1	2.42 million shs	5.34 million shs
BCYC Bicycle Therapeutics	$7.10 -1.4%	$7.66	$6.10 ▼ $28.67	$511.09M	1.41	251,371 shs	180,495 shs
BHC Bausch Health Cos	$7.37 -4.1%	$6.80	$4.25 ▼ $9.85	$2.75B	0.48	4.49 million shs	2.69 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.46%	+3.41%	+12.31%	+20.94%	-9.21%
ARWR Arrowhead Pharmaceuticals	+8.26%	+27.58%	+68.79%	+68.89%	+21.34%
BCYC Bicycle Therapeutics	-1.39%	+1.43%	-11.80%	-16.47%	-65.91%
BHC Bausch Health Cos	-4.16%	+1.24%	+27.53%	+59.24%	+21.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3533 of 5 stars	3.4	1.0	4.3	4.2	0.8	1.9
ARWR Arrowhead Pharmaceuticals	4.2054 of 5 stars	4.5	1.0	3.4	2.8	2.5	0.0
BCYC Bicycle Therapeutics	2.8761 of 5 stars	3.4	3.0	0.0	2.5	2.5	0.6
BHC Bausch Health Cos	4.4358 of 5 stars	2.0	3.0	4.0	4.0	4.2	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	38.72% Upside
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	55.19% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$22.22	212.99% Upside
BHC Bausch Health Cos	2.00	Hold	$9.00	22.20% Upside

Current Analyst Ratings Breakdown

Latest BCYC, BHC, AGIO, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
8/12/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $10.00
8/12/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $13.00
8/11/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$27.00
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/11/2025	BCYC Bicycle Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00 ➝ $44.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00

(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	64.64	N/A	N/A	$23.57 per share	1.72
ARWR Arrowhead Pharmaceuticals	$3.55M	1,082.71	N/A	N/A	$3.76 per share	7.39
BCYC Bicycle Therapeutics	$35.28M	13.94	N/A	N/A	$9.66 per share	0.73
BHC Bausch Health Cos	$9.63B	0.28	$7.67 per share	0.96	$0.40 per share	18.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.69	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
BCYC Bicycle Therapeutics	-$169.03M	-$3.51	N/A	N/A	N/A	-1,257.00%	-32.43%	-26.80%	10/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	$0.26	28.33	1.58	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)

Latest BCYC, BHC, AGIO, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	-$1.14	-$0.19	-$1.14	$9.43 million	$2.90 million
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
BCYC Bicycle Therapeutics	N/A	10.39	10.39
BHC Bausch Health Cos	141.90	1.31	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ARWR Arrowhead Pharmaceuticals	62.61%
BCYC Bicycle Therapeutics	86.15%
BHC Bausch Health Cos	78.65%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.93%
ARWR Arrowhead Pharmaceuticals	4.30%
BCYC Bicycle Therapeutics	8.50%
BHC Bausch Health Cos	19.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.24 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.37 million	Optionable
BHC Bausch Health Cos	20,700	370.13 million	296.21 million	Optionable

BCYC, BHC, AGIO, and ARWR Headlines

Recent News About These Companies

Quarry LP Invests $356,000 in Bausch Health Cos Inc. $BHC

September 3 at 6:21 AM | marketbeat.com

Nomura Holdings Inc. Has $151.37 Million Stake in Bausch Health Cos Inc. $BHC

September 2 at 7:09 AM | marketbeat.com

Nuveen LLC Buys New Position in Bausch Health Cos Inc. $BHC

September 2 at 3:31 AM | marketbeat.com

Jump Financial LLC Invests $1.06 Million in Bausch Health Cos Inc. $BHC

September 1 at 4:24 AM | marketbeat.com

Deutsche Bank AG Sells 2,099,217 Shares of Bausch Health Cos Inc. $BHC

September 1 at 3:31 AM | marketbeat.com

Bausch Health Launches YUN Probiotherapy(TM) ACN Skincare Line in Poland

September 1 at 2:51 AM | uk.finance.yahoo.com

Bausch (BHC) Up 21.4% Since Last Earnings Report: Can It Continue?

August 29, 2025 | zacks.com

Bausch Health Companies Inc. (BHC) Expands Hepatology Portfolio with DURECT Acquisition

August 29, 2025 | finance.yahoo.com

Charles Schwab Investment Management Inc. Increases Holdings in Bausch Health Cos Inc. $BHC

August 28, 2025 | marketbeat.com

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

August 26, 2025 | accessnewswire.comA

Bausch Health Cos Inc. $BHC Stake Increased by Vanguard Group Inc.

August 26, 2025 | marketbeat.com

Zacks Research Expects Lower Earnings for Bausch Health Cos

August 26, 2025 | americanbankingnews.com

Zacks Research Issues Pessimistic Forecast for BHC Earnings

August 26, 2025 | marketbeat.com

Q3 EPS Forecast for Bausch Health Cos Increased by Analyst

August 24, 2025 | marketbeat.com

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

August 21, 2025 | accessnewswire.comA

Bausch Health Cos (NYSE:BHC) Stock Price Down 4.5% - Time to Sell?

August 20, 2025 | marketbeat.com

Icahn representations resign Bausch + Lomb board after agreement termination

August 19, 2025 | msn.com

Bausch + Lomb board members resign after Icahn agreement ends

August 18, 2025 | reuters.com

TSX Today: What to Watch for in Stocks on Monday, August 18

August 18, 2025 | msn.com

Bausch Health (BHC) Climbs 45% on Insider Buying

August 18, 2025 | msn.com

Bausch Health Cos Sees Unusually Large Options Volume (NYSE:BHC)

August 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, BHC, AGIO, and ARWR Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$40.61 +1.36 (+3.46%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$40.62 +0.01 (+0.02%)

As of 09/3/2025 06:27 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$27.80 +2.12 (+8.26%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$27.91 +0.11 (+0.40%)

As of 09/3/2025 07:48 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bicycle Therapeutics NASDAQ:BCYC

$7.10 -0.10 (-1.39%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$7.06 -0.04 (-0.62%)

As of 09/3/2025 07:04 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bausch Health Cos NYSE:BHC

$7.36 -0.32 (-4.10%)

Closing price 09/3/2025 03:59 PM Eastern

Extended Trading

$7.41 +0.05 (+0.67%)

As of 09/3/2025 07:46 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time